Progress of immune check-point inhibitors’ application in advanced gastric cancer / 国际外科学杂志

ABSTRACT

China is one of the countries with the highest prevalence of gastric cancer, who the majority gastric cancers are advanced stage diseases. Multi-disciplinary treatment including surgery and chemotherapy is not sufficient to effectively improve the prognosis of late-stage gastric cancer. In recent years, immune check-point inhibitor has gained promising results in assorted types of cancers. Therefore, its application in gastric cancer has drew increasing attention. This article will review recent clinical researches and introduced the current clinical application of immune check-point inhibitors in the treatment of gastric cancer. For late-stage gastric cancer patients after failed attempts of treatment by conventional chemotherapy, PD-1 inhibitor is a viable option. Pembrolizumab is currently the only PD-1 inhibitor approved by FDA for application in gastric cancer, whereas CFDA has not approved any immune check-point inhibitors for this purpose. One of the major focus of subsequent basic and clinical researches will be how to further increase the objective response rate of anti-PD-1 treatment.